Patents by Inventor Elizabeth Gabitzsch
Elizabeth Gabitzsch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12290558Abstract: Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Also disclosed are compositions for assaying the presence of anti-viral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.Type: GrantFiled: October 17, 2023Date of Patent: May 6, 2025Assignee: ImmunityBio, Inc.Inventors: Patrick Soon-Shiong, Peter Sieling, Kayvan Niazi, Shahrooz Rabizadeh, Lise Geissert, Annie Shin, Adrian Rice, Elizabeth Gabitzsch, Jeffrey Safrit, Leonard Sender
-
Patent number: 12274748Abstract: An immunotherapeutic composition is contemplated that comprises subject-derived peripheral blood mononuclear cells (PBMC) and at least one recombinant adenovirus subtype 5 (Ad5) comprising a deletion in an E1 gene region, a deletion in an E2b gene region, and a nucleic acid sequence encoding a peptide antigen, wherein the PBMC are exposed ex-vivo to the at least one Ad5 vector. Advantageously, the same PBMC composition may also be used to prepare modified NK cells, and especially modified NK include CIML NK cells, CENK cells and mCENK cells.Type: GrantFiled: April 29, 2024Date of Patent: April 15, 2025Assignee: ImmunityBio, Inc.Inventors: Patrick Soon-Shiong, Elizabeth Gabitzsch, Philip T. Liu
-
Publication number: 20240366764Abstract: An immunotherapeutic composition is contemplated that comprises subject-derived peripheral blood mononuclear cells (PBMC) and at least one recombinant adenovirus subtype 5 (Ad5) comprising a deletion in an E1 gene region, a deletion in an E2b gene region, and a nucleic acid sequence encoding a peptide antigen, wherein the PBMC are exposed ex-vivo to the at least one Ad5 vector. Advantageously, the same PBMC composition may also be used to prepare modified NK cells, and especially modified NK include CIML NK cells, CENK cells and mCENK cells.Type: ApplicationFiled: April 29, 2024Publication date: November 7, 2024Applicant: ImmunityBio, Inc.Inventors: Patrick Soon-Shiong, Elizabeth Gabitzsch
-
Publication number: 20240075129Abstract: Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Also disclosed are compositions for assaying the presence of anti-viral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.Type: ApplicationFiled: October 17, 2023Publication date: March 7, 2024Applicant: ImmunityBio, Inc.Inventors: Patrick Soon-Shiong, Peter Sieling, Kayvan Niazi, Shahrooz Rabizadeh, Lise Geissert, Annie Shin, Adrian Rice, Elizabeth Gabitzsch, Jeffrey Safrit, Leonard Sender
-
Patent number: 11857620Abstract: Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Also disclosed are compositions for assaying the presence of antiviral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.Type: GrantFiled: March 10, 2021Date of Patent: January 2, 2024Assignee: ImmunityBio, Inc.Inventors: Patrick Soon-Shiong, Peter Sieling, Kayvan Niazi, Shahrooz Rabizadeh, Lise Geissert, Annie Shin, Adrian Rice, Elizabeth Gabitzsch, Jeffrey Safrit, Leonard Sender
-
Publication number: 20230348935Abstract: Vaccine compositions are provided that comprise a lyophilized, adenovirus-based expression vector, and a stabilizing compound, such as such as aragonite. Further provided are compositions that include a solid dosage form made from aragonite for loading and delivery of a vaccine composition.Type: ApplicationFiled: October 22, 2021Publication date: November 2, 2023Inventors: Patrick SOON-SHIONG, Elizabeth GABITZSCH, Victor PEYKOV
-
Publication number: 20230338508Abstract: Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Also disclosed are compositions for assaying the presence of antiviral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.Type: ApplicationFiled: March 10, 2021Publication date: October 26, 2023Inventors: Patrick Soon-Shiong, Peter Sieling, Kayvan Niazi, Shahrooz Rabizadeh, Lise Geissert, Annie Shin, Adrian Rice, Elizabeth Gabitzsch, Jeffrey Safrit, Leonard Sender
-
Publication number: 20230086390Abstract: Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Also disclosed are compositions for assaying the presence of antiviral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.Type: ApplicationFiled: March 10, 2021Publication date: March 23, 2023Inventors: Patrick Soon-Shiong, Peter Sieling, Kayvan Niazi, Shahrooz Rabizadeh, Lise Geissert, Annie Shin, Adrian Rice, Elizabeth Gabitzsch, Jeffrey Safrit, Leonard Sender
-
Patent number: 11352642Abstract: Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.Type: GrantFiled: January 7, 2016Date of Patent: June 7, 2022Assignee: Etubics CorporationInventors: Frank R. Jones, Elizabeth Gabitzsch, Yvette Latchman, Adrian Rice
-
Patent number: 11304998Abstract: Methods and compositions for generating enhanced immune responses using adenovirus vectors that allow for multiple vaccinations in combination with an IL-15 superagonist complex in subjects in need thereof are provided.Type: GrantFiled: April 26, 2021Date of Patent: April 19, 2022Assignee: Etubics CorporationInventors: Frank R. Jones, Adrian Rice, Elizabeth Gabitzsch, Yvette Latchman, Joseph Balint
-
Patent number: 11149087Abstract: Methods and compositions for generating immune responses using adenovirus vectors that allow multiple vaccinations or in combination with other therapy and vaccinations in individuals with preexisting immunity to adenovirus are provided.Type: GrantFiled: April 20, 2016Date of Patent: October 19, 2021Assignee: Etubics CorporationInventors: Frank R. Jones, Elizabeth Gabitzsch, Yvette Latchman, Adrian Rice
-
Patent number: 11116827Abstract: In certain embodiments, methods and compositions are provided for generating immune responses against tumor antigens such as antigens or epitopes of HER1, HER2/neu, HER3, HER4, or any combination thereof. In particular embodiments, there may be provided methods for constructing and producing recombinant adenovirus-based vector vaccines containing nucleic acid sequences encoding tumor antigens such as antigens or epitopes of HER1, HER2/neu, HER3, HER4, or any combination thereof, that allow for vaccinations in individuals with preexisting immunity to adenovirus.Type: GrantFiled: June 2, 2018Date of Patent: September 14, 2021Assignee: Etubics CorporationInventors: Frank R. Jones, Joseph Balint, Elizabeth Gabitzsch
-
Patent number: 11104916Abstract: Compositions of a recombinant adenovirus based vector vaccine containing one or more alphavirus antigen genes are disclosed herein. Methods for constructing and producing such vaccines and methods of using these vaccines to generate broad based immune responses against alphaviruses are also described. Compositions described herein allow for vaccinations in individuals with preexisting immunity to adenovirus.Type: GrantFiled: July 14, 2017Date of Patent: August 31, 2021Assignee: Etubics CorporationInventors: Frank R. Jones, Joseph Balint, Adrian Rice, Yvette Latchman, Elizabeth Gabitzsch
-
Publication number: 20210260175Abstract: Methods and compositions for generating enhanced immune responses using adenovirus vectors that allow for multiple vaccinations in combination with an IL-15 superagonist complex in subjects in need thereof are provided.Type: ApplicationFiled: April 26, 2021Publication date: August 26, 2021Inventors: Frank R. Jones, Adrian Rice, Elizabeth Gabitzsch, Yvette Latchman, Joseph Balint
-
Patent number: 11020467Abstract: Methods and compositions for generating enhanced immune responses using adenovirus vectors that allow for multiple vaccinations in combination with an IL-15 superagonist complex in subjects in need thereof are provided.Type: GrantFiled: May 25, 2018Date of Patent: June 1, 2021Assignee: Etubics CorporationInventors: Frank R. Jones, Adrian Rice, Elizabeth Gabitzsch, Yvette Latchman, Joseph Balint
-
Patent number: 10835596Abstract: Compositions of a recombinant adenovirus based vector vaccine containing one or more flavivirus antigen genes are disclosed herein. Methods for constructing and producing such vaccines and methods of using these vaccines to generate immune responses against flaviviruses are also described. Compositions described herein allow for vaccinations in subjects with preexisting immunity to adenovirus.Type: GrantFiled: July 14, 2017Date of Patent: November 17, 2020Assignee: Etubics CorporationInventors: Frank R. Jones, Joseph Balint, Adrian Rice, Yvette Latchman, Elizabeth Gabitzsch
-
Patent number: 10695417Abstract: Methods for generating immune responses to Ebola virus antigens using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.Type: GrantFiled: January 7, 2016Date of Patent: June 30, 2020Assignee: Etubics CorporationInventors: Frank R. Jones, Elizabeth Gabitzsch
-
Publication number: 20200171140Abstract: Compositions of a recombinant adenovirus based vector vaccine containing one or more flavivirus antigen genes are disclosed herein. Methods for constructing and producing such vaccines and methods of using these vaccines to generate immune responses against flaviviruses are also described. Compositions described herein allow for vaccinations in subjects with preexisting immunity to adenovirus.Type: ApplicationFiled: July 14, 2017Publication date: June 4, 2020Applicant: ETUBICS CORPORATIONInventors: Frank R. JONES, Joseph BALINT, Adrian RICE, Yvette LATCHMAN, Elizabeth GABITZSCH
-
Publication number: 20200172925Abstract: Compositions of a recombinant adenovirus based vector vaccine containing one or more alphavirus antigen genes are disclosed herein. Methods for constructing and producing such vaccines and methods of using these vaccines to generate broad based immune responses against alphaviruses are also described. Compositions described herein allow for vaccinations in individuals with preexisting immunity to adenovirus.Type: ApplicationFiled: July 14, 2017Publication date: June 4, 2020Applicant: ETUBICS CORPORATIONInventors: Frank R. JONES, Joseph BALINT, Adrian RICE, Yvette LATCHMAN, Elizabeth GABITZSCH
-
Publication number: 20200155662Abstract: Methods and compositions for generating enhanced immune responses using adenovirus vectors that allow for multiple vaccinations in combination with an IL-15 superagonist complex in subjects in need thereof are provided.Type: ApplicationFiled: May 25, 2018Publication date: May 21, 2020Inventors: Frank R. JONES, Adrian RICE, Elizabeth GABITZSCH, Yvette LATCHMAN, Joseph BALINT